Product Information
OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN is a brand product labeled by Novo Nordisk, priced at $331.9909 per ML under NDC 00169418113. Its NADAC has been published 177 times since May 17, 2023.
FDA first approved this application on Dec 5, 2017.
Strength
.68 mg/mL
Manufacturer
Novo NordiskNDC
00169418113
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
SEMAGLUTIDEApproval Type
New Drug (NDA)
FDA Application
NDA209637FDA Approved
12/5/2017
On Market Since
10/7/2022
Pharmacological Classes
Price Statistics
The NADAC for OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN has been published 177 times since May 17, 2023, and over the history we have for it it has risen 10.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $331.9909 per ML |
|---|---|
| All-time high | $332.0230 (May 13, 2026) |
| All-time low | $300.0559 (May 17, 2023) |
| 52-week high | $332.0230 |
| 52-week low | $322.3088 |
| Median price | $321.2146 |
| Average price | $316.9073 |
| Largest weekly change | +3.5% (Jan 10, 2024) |
| Weeks tracked | 177 |
| Tracking since | May 17, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the semaglutide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novo Nordisk manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
semaglutide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
GLP-1 Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN?
The current National Average Drug Acquisition Cost (NADAC) for OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN, manufactured by Novo Nordisk, is $331.9909 per ML (NDC 00169418113), effective Sep 30, 2026.
How has the price of OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN changed over time?
Over the history we have for it, the NADAC for OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN has risen 10.6%. It has been tracked across 177 weekly CMS publications since May 17, 2023.
What are the highest and lowest recorded NADAC prices for OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN?
Since May 17, 2023, the NADAC for OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN has ranged from a low of $300.0559 (May 17, 2023) to a high of $332.0230 (May 13, 2026), with a median of $321.2146 per ML.
Are there cheaper alternatives to OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN?
No other NADAC-published product currently shares the active ingredient and strength of OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN?
OZEMPIC 0.25-0.5 MG/DOSE (2 MG/3 ML) PEN (NDC 00169418113) is labeled by Novo Nordisk, and CMS classifies it as a brand product.